FDA reviewing sBLA for Pegintron for melanoma
Schering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma.
KENILWORTH, New JerseySchering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma. The agent is currently approved for use in the treatment of chronic hepatitis C. The company said that FDA's Oncology Drugs Advisory Committee will discuss the application at its meeting in March.
Articles in this issue
NLST article not balanced, critic of screening trial asserts
M.D. Anderson and AstraZeneca form neuropathic pain alliance
Good nilotinib responses in imatinib-resistant AP-CML
Virus linked to Merkel cell carcinoma
Benefit of adjuvant RT/CT for pancreatic ca affirmed
Recurrence Score helps select node+ pts for chemo
For resectable liver mets: Preop chemotherapy or not?
Plerixafor boosts stem cell mobilization in myeloma pts
MRI shows second-hand smoke damage
Assay has high sensitivity for hard-to-detect SLN mets
Dasatinib effective in imatinib resistant/intolerant CML
ONI remembers Judah Folkman, founder of angiogenesis
New machine approved for adaptive RT
ONI sits down with Dr. Vincent DeVita
Making faster, better, more cost-effective clinical trials
Recent Videos
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
